Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease. According to the insights of surveyed U.S. and European pulmonologists, greater reduction in exacerbation rate and greater improvement in quality of life are key areas of unmet need for moderate to severe asthma. Furthermore, novel agents with strong efficacy in reducing the rate of exacerbations will have considerable influence on physician prescribing decisions as competition among pharmacological agents rapidly increases in the moderate to severe asthma market.

Table of contents

  • Detailed, Expanded Analysis (Moderate to Severe Asthma)
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Non-Clinical Attributes
        • Rationale for Treatment Drivers and Goals Selection
      • Physician Rating of Treatment Drivers and Goals in Moderate to Severe Asthma
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Stated Versus Derived Importance of Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Moderate to Severe Asthma
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Unmet Need in Moderate to Severe Asthma and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Moderate to Severe Asthma Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent Capable of Substantially Reducing Exacerbation Rates in Moderate to Severe Asthma Patients
        • Opportunity: A New Therapy with Efficacy in Reducing OCS Use in Moderate to Severe Asthma
        • Opportunity: A New Agent with Efficacy Demonstrated in a Broad Patient Population Regardless of Patient Phenotype
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2

Author(s): Eun-Jin Yang, PhD

Eun-Jin Yang, . is a senior business insights analyst at Decision Resources Group. She has authored market research reports analyzing physician, payer, and market trends in asthma, COPD, Lupus, and other autoimmune diseases. Her prior experience includes publishing pharmaceutical and biotechnology company-focused industry research articles as a cofounding analyst in the Harvard Biotechnology Club and helping to commercialize inventions in various therapeutic areas from Massachusetts General Hospital and Brigham and Women’s Hospital. She finished her postdoctoral fellowships at Boston Children’s Hospital, Harvard University, and Columbia University. She received her at the University of Texas at Austin.


Related Reports

Asthma | Emerging Therapies | Dupixent (Dupilumab) (US) Wave 3

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of...

View Details

Asthma | Landscape & Forecast | Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim&rsquo...

View Details

Asthma | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details

Chronic Obstructive Pulmonary Disease | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details